1. CSL Behring Germany. Corifact, Faktor XIII Concentrate (Human) Prescribing Information. 2011. https://www.fda.gov/media/80181/download
2. CSL Behring Canada. Corifact 250/Corifact 1250 Faktor XIII Concentrate, Human Product Monograph. 2018. https://labeling.cslbehring.ca/PM/CA/Corifact/EN/Corifact-Product-Monograph.pdf
3. Lassila R. Clinical Use of Factor XIII Concentrates. Semin Thromb Hemost. 2016 Jun;42(4):440-4.
7. Goldenberg MM. Pharmaceutical approval update. P T. 2012 Nov;37(11):620-49. Erratum in: P T. 2012 Dec;37(12):658.
8. Medscape. Faktor XIII concentrate, human (Rx). 2023. https://reference.medscape.com/drug/corifact-faktor-xiii-concentrate-human-999624
11. Inbal A. Recombinant faktor XIII (rFXIII): a novel treatment of congenital faktor XIII deficiency. Clin. Invest. (Lond.). 2015;5(2):137-143.
15. Kerlin B, Brand B, Inbal A, Halimeh S, Nugent D, Lundblad M, Tehranchi R. Pharmacokinetics of recombinant faktor XIII at steady state in patients with congenital faktor XIII A-subunit deficiency. Journal of Thrombosis and Haemostasis. 12:2038-2043.
18. Muszbek L dan Katona E. Diagnosis and Management of Congenital and Acquired FXIII Deficiencies. Semin Thromb Hemost. 2016;42(4):429-39.
19. Beckman JD, Holle LA, Wolberg AS. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking. J Thromb Haemost. 2018. 16(1):131-141.